PharmaMar Presents the Overall Survival Data From the Phase I/II Study of lurbinectedin in Combination With Doxorubicin for Relapsed Small Cell Lung Cancer Sep 24, 2018 04:46PM
PharmaMar Will Present the Results of the Phase I/II Study With Lurbinectedin in Combination With Doxorubicin in Relapsed Small-cell Lung Cancer During the IASLC World Conference Sep 6, 2018 08:30AM
PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis® in the Nordic Countries and Eastern Europe Jul 27, 2018 08:18AM
PharmaMar and Chugai Agree to Terms for Early Termination of the License Agreement for Zepsyre® in Japan Jun 26, 2018 01:13PM
PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin® With Pint Pharma International Jun 11, 2018 08:30AM


Jun 5, 2018 08:30AM PharmaMar Presents in Oral Session at ASCO: The ADMYRE Study's Adjusted Overall Survival With Plitidepsin
May 29, 2018 08:30AM Positive Recommendation of IDMC to Zepsyre® to Continue the Phase III Trial Within Small-cell Lung Cancer (ATLANTIS)
Nov 4, 2017 08:30AM PharmaMar Announces Partnership with 8th National Race to End Women's Cancer in Support of "End Women´s Cancer Weekend" in Washington D.C.
Oct 10, 2016 09:00AM PharmaMar Announces Positive Results From its Phase II Study With lurbinectedin in BRCA 1/2 - Associated Metastatic Breast Cancer at the ESMO 2016 Congress
May 19, 2016 09:00AM PharmaMar Reports Positive Results from the Phase I Study of plitidepsin in Combination with bortezomib and dexamethasone in Patients with Multiple Myeloma at the 2016 ASCO Annual Meeting
May 19, 2016 09:00AM PharmaMar Announces New Data on Yondelis®, plitidepsin and PM1183 to be Presented at 2016 ASCO Annual Meeting